New immunotherapy combo for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) for people with newly diagnosed, advanced head and neck cancer that hasn't spread to distant parts of the body. The goal is to see if this treatment can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are newly diagnosed with advanced head and neck cancer (stage 3 or 4) that has not been treated before.
- You have not had chemotherapy or radiation for head and neck cancer, and you have not had surgery to completely remove the cancer.
- You are in good enough health to be up and about (ECOG score 0 or 1).
- Your blood counts and organ function (kidney, liver) are within certain safe ranges.
- If you have HPV-related oropharynx cancer, it must be a specific advanced stage (T4 or N3).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different immunotherapy approaches for people with HPV-positive oropharyngeal cancer who have completed initial treatment like surgery, radiation, or chemotherapy. The goal is to see which option works better to keep the cancer from coming back, and eligibility is determined by a special blood test that detects HPV DNA.
This Phase 1 trial tests how well cemiplimab (an immune treatment) can work when combined with chemotherapy and an additional immunotherapy for certain head and neck cancers. It may help shrink the cancer and improve outcomes, while also checking safety and dosing.
This study compares a new combination of two drugs (fianlimab and cemiplimab) against cemiplimab alone for people with head and neck cancer that has returned or spread. It aims to see if the combination works better.
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.
This trial tests a new combination of two immunotherapy drugs (called iparomlimab and tuvonralimab), with or without chemotherapy, for head and neck squamous cell carcinoma that has returned or spread after previous treatment. The goal is to see if this combination can help people with this cancer live longer with fewer side effects.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.